Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nick Holford

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
British Journal of Clinical Pharmacology|June 5, 2023
Evaluation of the Prescribing Skills Assessment implementation, performance and medical student experience in Australia and New ZealandPaul K L Chin, Kellie Charles, Bridin Murnion, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 3, 2024
Covariate modeling in pharmacometrics: General points for considerationKinjal Sanghavi, Jakob Ribbing, James A Rogers, et al.
Blood|August 12, 2006
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamicsDaniel J DeAngelo, Richard M Stone, Mark L Heaney, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
British Journal of Clinical Pharmacology|June 5, 2023
Evaluation of the Prescribing Skills Assessment implementation, performance and medical student experience in Australia and New ZealandPaul K L Chin, Kellie Charles, Bridin Murnion, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 3, 2024
Covariate modeling in pharmacometrics: General points for considerationKinjal Sanghavi, Jakob Ribbing, James A Rogers, et al.
Blood|August 12, 2006
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamicsDaniel J DeAngelo, Richard M Stone, Mark L Heaney, et al.
Pageof 4